Ascilion develops a patented microneedle-based extraction system intended for minimally invasive dermal sampling of interstitial fluid. The development of the silicon-based microneedles is in the forefront of micro electro mechanical systems (MEMS) technology and the needles are manufactured using state-of-the-art processing. The business idea is to replace traditional blood sampling with this painless and easy to use technology in research as well as clinical settings, e.g. in connection with glucose monitoring. Ascilion is currently financed as a startup, now ready to take the first steps towards commercialization. The company is located in Kista/Stockholm. For more information visit www.ascilion.com
Ascilion has developed an innovative method, using a proprietary array of tiny hollow microneedles, for pain-free extraction of biomarker carrying interstitial fluid (ISF) from the skin. The technology enables a new era of blood- and pain-free disease monitoring and diagnostics with practical implications for healthcare as well as for scientific and drug discovery purposes. Clinical and research partnerships have been initiated with good results.
You will be instrumental in initiating and leading global collaborations and commercialization of the developed microneedle technology and products. This will require new initiatives with focus on organizational development, commercial and financial partnerships as well as EU and US regulatory groundwork. The final “go-to market plan” will build on establishing partnerships within several verticals, e.g. diabetes/glucose monitoring, neonatal care, allergy treatment, drug- and skin cosmetics development.
For more information, please contact K2 Search, Senior Consultant Arne Nordström, +46 70 698 92 00 or Senior Research Consultant Petter Pålsson, +46 73 521 65 55. All contacts are handled with strict confidentiality.